Demethylzeylasteral Composition for Glucocorticoid-Linked Muscle Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sarcopenia and other muscle-wasting diseases are inadequate, and there is a need for a pharmaceutical composition that can prevent or treat muscle loss by addressing hormonal imbalances and muscle degradation.
Innovation Solution
A pharmaceutical composition containing demethylzeylasteral, a triterpenoid compound, acts as an antagonist of the glucocorticoid receptor, regulating gene transcription and promoting muscle differentiation while inhibiting muscle degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoid levels are increased to treat inflammation or immune conditions, then immune response is enhanced, but muscle mass and strength deteriorate due to activation of atrophy genes
Solution Approach 1:
The patent introduces a glucocorticoid receptor antagonist as an intermediary substance that blocks the harmful effects of glucocorticoids on muscle tissue while allowing the glucocorticoids to continue functioning in the immune system. This mediator prevents the activation of atrophy genes (atrogin1, MuRF1) in muscle cells, thereby protecting muscle mass and strength while maintaining immune response.
Solution Approach 2:
The patent applies local quality by targeting the specific interaction between glucocorticoids and muscle tissue through the glucocorticoid receptor antagonist. The antagonist is selectively active in muscle tissue to prevent local muscle degradation, while the glucocorticoids can still exert their systemic immune effects. This localized intervention protects muscle without compromising overall immune function.
2Strength
If glucocorticoid receptor antagonists are used to protect muscle mass, then muscle degradation is inhibited, but the complexity of the pharmaceutical composition increases
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of the glucocorticoid receptor antagonist to optimize its binding affinity and selectivity. By adjusting molecular parameters such as the presence of specific functional groups (e.g., hydroxyl, carbonyl, carboxyl groups) and steric configurations, the compound achieves high potency and specificity for the glucocorticoid receptor, thereby protecting muscle mass with a well-defined molecular mechanism that manages composition complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Demethylzeylasteral effectively transforms myoblasts into myotubes, promotes muscle differentiation, and inhibits muscle degradation, providing a therapeutic and preventive effect against muscle-wasting diseases.
Implementation Method 1
acts as an antagonist of the glucocorticoid receptor, regulating gene transcription and promoting muscle differentiation while inhibiting muscle degradation
Data Source
AI summary
A method for ameliorating or treating a disease caused by muscle loss includes administering a composition including a compound represented by Formula 1 or a salt thereof to a subject in need thereof. The disease caused by muscle loss may be sarcopenia, muscular dystrophy, myasthenia, myodystrophia, myotonia, muscular hypotonia, muscular weakness, myotonic dystrophy, amyotrophic lateral sclerosis, and/or myasthenia gravis.